QSAM Biosciences receives second key patent in Europe for CycloSam

QSAM Biosciences announced that the European Patent Office, EPO, has allowed a key patent that protects the use of "lower specific activity" Samarium-153 in conjunction with the treatment of bone cancer in children and adults. This new patent in Europe covers the "high purity therapeutic bone agents" technology exclusively licensed to QSAM on a worldwide basis and relates to the novel manner in which the Samarium-153 is produced for use in CycloSam. "We believe that repeated dose regimens of CycloSam(R) may be the key to being able to successfully treat bone tumors, and we are continuing to advance our clinical trials program to generate data toward that goal," stated Douglas Baum, CEO and co-founder of the Company. "This allowance by the EPO marks our second patent in Europe, and we expect to register the patent in multiple individual countries in the EU over the following few weeks, thereby expanding our already established and robust patent estate. More so, this additional IP protection broadens our potential commercial market for what we believe may eventually be a breakthrough therapy for both primary and secondary forms of bone cancer," added Baum.